Acinetobacter phages use distinct strategies to breach the capsule barrier
PLOS Pathogens · 29.09.2025 · 21 (9) · e1013536
DOI: 10.1371/journal.ppat.1013536 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 29.09.2025. Verfasst von Alexis J McCalla und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology, Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, United States of America. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Bacteriophages, Bacterial Capsules, Acinetobacter Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, Washington University.
Abstract (Originalsprache)
Acinetobacter baumannii is an opportunistic pathogen that is a growing threat in hospital settings due to its alarmingly high rates of antibiotic resistance. Alternative therapies are urgently needed to manage the growing burden of untreatable A. baumannii infections. Phage therapy is a promising avenue that has already seen some success in isolated compassionate-use cases, including the famous “Patterson case”. Bacterial surface structures are the first determinants of susceptibility to phage infection and play a major role in phage host range. Most A. baumannii strains produce a protective capsule that is highly diverse both in structure and composition, and provides the first immunity barrier against phages. Here, we perform a detailed molecular characterization of three recently isolated, distinct A. baumannii phages, StAb1, StAb2, and StAb3, that breach the capsule via different mechanisms. Like many previously described A. baumannii phages, a specific capsule type is necessary for StAb1 infection. We found that StAb2 and its relatives adsorb to either a specific capsule type or the conserved outer membrane protein CarO, a porin normally occluded by the capsule. Thus, this phage has a narrow host range amongst capsulated strains, but can broadly infect A. baumannii strains lacking capsule. We also show that StAb3 requires a conserved and uncharacterized glycan that we have termed phage glycan receptor (PGR) that enables StAb3 to infect a broad range of A. baumannii strains irrespective of whether capsule is present. We demonstrate how rationally combining phages with distinct capsule interactions reduces the rapid emergence of phage escape mutants, with potential applications for more effective phage therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Molecular Microbiology, Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, United States of America.
ORCID-Profile: Mario F Feldman, Michele LeRoux
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- Washington University
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
McCalla, A. J., Walker, F. C., Bisaro, F., Rodriguez-Anavitate, M., Johannesman, A., Di Venanzio, G., Feldman, M. F., & LeRoux, M. (2025). Acinetobacter phages use distinct strategies to breach the capsule barrier. PLOS Pathogens, 21(9), e1013536. https://doi.org/10.1371/journal.ppat.1013536
Vancouver
McCalla AJ, Walker FC, Bisaro F, Rodriguez-Anavitate M, Johannesman A, Di Venanzio G, et al. Acinetobacter phages use distinct strategies to breach the capsule barrier. PLOS Pathogens. 2025;21(9):e1013536. doi:10.1371/journal.ppat.1013536
BibTeX
@article{McCalla2025,
author = {McCalla, Alexis J and Walker, Forrest C and Bisaro, Fabiana and Rodriguez-Anavitate, Miguel and Johannesman, Anna and Di Venanzio, Gisela and Feldman, Mario F and LeRoux, Michele},
title = {Acinetobacter phages use distinct strategies to breach the capsule barrier},
journal = {PLOS Pathogens},
year = {2025},
volume = {21},
number = {9},
pages = {e1013536},
doi = {10.1371/journal.ppat.1013536}
}
EUVIMED